A Study of Olomorasib (LY3537982) in Healthy Japanese Participants

Inclusion criteria

• Japanese participants who are overtly healthy as determined by medical evaluation including medical history, 12 lead electrocardiogram (ECG), vital sign measurements, and clinical laboratory evaluations.
• Have a body mass index within the range 18.5 to 30.0 kilograms per square meter (kg/m²), inclusive, at screening.
• Participants assigned male at birth (AMAB) may participate in this study.

Exclusion criteria

• Have a history of malignancy within 5 years prior to screening except for basal cell or squamous epithelial carcinomas of the skin or in situ carcinoma of the cervix that have been resected with no evidence of metastatic disease for 3 years.
• Have known allergies to olomorasib or any component of the formulation, or related compounds.
• Use of any other investigational drug or device within 30 days or 5 half-lives (if known), whichever is longer, of the first dose of study drug.
• Have previously completed or withdrawn from this study or any other study investigating olomorasib and have previously received olomorasib
• Show evidence of hepatitis B or positive hepatitis B surface antigen.
• Show evidence of hepatitis C or have a positive hepatitis C virus antibody test.
• Show evidence of HIV infection or positive HIV antigen or HIV antibodies.
• Show evidence of syphilis or have a positive syphilis test.